Información del producto
KT182 is a potent and selective CB1 receptor antagonist that has been shown to inhibit the hydrolysis of 2-arachidonoylglycerol (2-AG) by blocking the binding of fatty acids to the enzyme monoacylglycerol lipase (MAGL). It also blocks some of the effects of endocannabinoids, such as inhibition of microglia and nitrogen atoms. KT182 has been tested in animal studies for metabolic disorders, with promising results. This drug is not orally active and must be administered intravenously. KT182 may be useful for treating obesity, type II diabetes, and other metabolic disorders.
Propiedades químicas
Consulta técnica sobre: 3D-CGC61262 KT182
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
